Development and validation of a predictive model for pathological upgrading in colorectal polyps based on endoscopic forceps biopsy.
[OBJECTIVES] To develop and validate a model for predicting the risk of pathological upgrading in patients with colorectal polyps.
APA
Cheng Z, Zhang C, Yu F (2026). Development and validation of a predictive model for pathological upgrading in colorectal polyps based on endoscopic forceps biopsy.. Frontiers in medicine, 13, 1748424. https://doi.org/10.3389/fmed.2026.1748424
MLA
Cheng Z, et al.. "Development and validation of a predictive model for pathological upgrading in colorectal polyps based on endoscopic forceps biopsy.." Frontiers in medicine, vol. 13, 2026, pp. 1748424.
PMID
41767522
Abstract
[OBJECTIVES] To develop and validate a model for predicting the risk of pathological upgrading in patients with colorectal polyps.
[METHODS] This prospective study enrolled 616 patients who were diagnosed with colorectal polyps by endoscopic forceps biopsy at the Fourth Affiliated Hospital of Anhui Medical University from August 2022 to October 2025. After exclusion, 593 patients were included in the final analysis. They were randomly divided into a training cohort ( = 415) and a testing cohort ( = 178) at a ratio of 7:3. In the training cohort, least absolute shrinkage and selection operator (LASSO) regression was used to select possible predictive factors. Multivariable logistic regression was then applied to identify independent risk factors. A nomogram was developed to show the prediction model in a visual way. The performance of the model was assessed using the receiver operating characteristic (ROC) curve, calibration plot, Hosmer-Lemeshow goodness-of-fit test, and decision curve analysis (DCA). SHapley Additive Explanations (SHAP) were also used to help explain the model results.
[RESULTS] The polyp was located in the rectum, with an MTD ≥ 30 mm. The polyp had a villous structure. Erosion of the polyp and redness of the polyp surface were identified as significant predictors of pathological escalation in patients with colorectal polyps. A nomogram developed based on these predictors showed excellent predictive performance. The area under the ROC curve (AUC) for the training set and the test set is 0.890 and 0.922, respectively. The calibration curve and the Hosmer-Lemeshow test show a high degree of consistency between the predicted and observed results, and DCA confirms that the model has superior clinical practicality.
[CONCLUSION] This study developed and validated a risk prediction model for pathological upgrade of colorectal polyps based on five endoscopic factors, including rectal location, maximum tumor diameter (MTD) ≥ 30 mm, villous structure, erosion, and a red surface color. The model serves as a practical clinical tool that allows endoscopists to assess patient risk with high accuracy before treatment. By helping identify high-risk polyps that may need wider resection or closer follow-up, the model supports more personalized treatment decisions and may reduce both under-treatment and over-treatment. Its use is expected to improve individual patient management and enhance the effectiveness of colorectal cancer prevention.
[METHODS] This prospective study enrolled 616 patients who were diagnosed with colorectal polyps by endoscopic forceps biopsy at the Fourth Affiliated Hospital of Anhui Medical University from August 2022 to October 2025. After exclusion, 593 patients were included in the final analysis. They were randomly divided into a training cohort ( = 415) and a testing cohort ( = 178) at a ratio of 7:3. In the training cohort, least absolute shrinkage and selection operator (LASSO) regression was used to select possible predictive factors. Multivariable logistic regression was then applied to identify independent risk factors. A nomogram was developed to show the prediction model in a visual way. The performance of the model was assessed using the receiver operating characteristic (ROC) curve, calibration plot, Hosmer-Lemeshow goodness-of-fit test, and decision curve analysis (DCA). SHapley Additive Explanations (SHAP) were also used to help explain the model results.
[RESULTS] The polyp was located in the rectum, with an MTD ≥ 30 mm. The polyp had a villous structure. Erosion of the polyp and redness of the polyp surface were identified as significant predictors of pathological escalation in patients with colorectal polyps. A nomogram developed based on these predictors showed excellent predictive performance. The area under the ROC curve (AUC) for the training set and the test set is 0.890 and 0.922, respectively. The calibration curve and the Hosmer-Lemeshow test show a high degree of consistency between the predicted and observed results, and DCA confirms that the model has superior clinical practicality.
[CONCLUSION] This study developed and validated a risk prediction model for pathological upgrade of colorectal polyps based on five endoscopic factors, including rectal location, maximum tumor diameter (MTD) ≥ 30 mm, villous structure, erosion, and a red surface color. The model serves as a practical clinical tool that allows endoscopists to assess patient risk with high accuracy before treatment. By helping identify high-risk polyps that may need wider resection or closer follow-up, the model supports more personalized treatment decisions and may reduce both under-treatment and over-treatment. Its use is expected to improve individual patient management and enhance the effectiveness of colorectal cancer prevention.
같은 제1저자의 인용 많은 논문 (5)
- Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma.
- Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
- Advances in Platinum(IV) Functional Axial Ligand Research: A Prospective Perspective.
- Empowerment of CAR-T Cells by IL-7 and IL-15 Boosts Their Efficacy Against HER2-Positive Tumors with Enhanced Expansion and Persistence.
- Discovery of novel bis-aryl urea-linked triazine derivatives as dual PI3K/mTOR inhibitors via scaffold hopping strategy and biological activity evaluations.